Business Context and Reporting Period
Company: Carpenter Technology Corporation (CRS)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended September 30, 2025 (Fiscal Q1 2026)
Business Overview: A producer and distributor of premium specialty alloys, including titanium, powder metals, stainless steels, and tool steels, serving aerospace, defense, medical, energy, and industrial markets.
Key Financial Metrics
| Metric ($ millions) | Q1 2026 (Sep 30, 2025) | Q1 2025 (Sep 30, 2024) |
|---|---|---|
| Net Sales | 733.7 | 717.6 |
| Gross Profit | 216.4 | 176.3 |
| Gross Margin | 29.5% | 24.6% |
| Operating Income | 153.3 | 113.6 |
| Operating Margin | 20.9% | 15.8% |
| Net Income | 122.5 | 84.8 |
| Diluted EPS | $2.43 | $1.67 |
| Operating Cash Flow | 39.2 | 40.2 |
| Capital Expenditures | 42.6 | 26.9 |
| Adjusted Free Cash Flow | (3.4) | 13.3 |
| Cash and Equivalents | 208.0 | 150.2 |
| Total Debt | 695.7 | 695.4 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2% year-over-year. Excluding raw material surcharges, sales grew 4%, driven by price increases and improved product mix.
- Profitability Expansion: Operating income rose 35% to $153.3 million. The Specialty Alloys Operations (SAO) segment achieved a record 15th consecutive quarter of increasing adjusted operating margins (32.0% excluding surcharges).
- Segment Performance:
- SAO: Sales up 2%; Operating income up 27% to $170.7 million.
- PEP: Sales down 7% to $93.6 million due to lower Medical and Distribution sales, though operating income improved to $9.4 million.
- Market Dynamics: Aerospace and Defense sales increased 8% (11% excluding surcharges). Medical sales declined 14% due to supply chain inventory management. Transportation sales fell 19% due to weaker consumer demand.
- Restructuring: No restructuring charges in Q1 2026 compared to $3.6 million in Q1 2025.
Guidance, Outlook, and Risks
- Outlook: Management expects future operating income growth driven by increasing sales, expanding margins, and productivity improvements. The Aerospace and Defense and Energy markets have a strong multi-year outlook.
- Capital Allocation: Capital expenditures for fiscal 2026 are expected to range from $280.0 million to $300.0 million, including a brownfield capacity expansion. The company continues to return cash via dividends ($0.20/share) and share repurchases ($49.1 million in Q1; $249.0 million remaining under the $400.0 million authorization).
- Tax Environment: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 includes changes to R&D deductions and bonus depreciation; specific financial impacts are not yet quantifiable.
- Risks:
- Government Shutdown: Monitoring potential impacts of a continued U.S. government shutdown.
- Tariffs: Monitoring evolving tariff news; surcharge mechanisms are in place to pass through raw material cost increases.
- Raw Materials: Volatility in raw material prices impacts margins, though hedging and surcharges mitigate risk.
Investor Verification Checklist
- Surcharge Impact: Verify the distinction between reported margins (diluted by surcharges) and adjusted margins (excluding surcharges) to assess core operational performance.
- Working Capital: Review the $36.2 million increase in accounts receivable, which negatively impacted operating cash flow compared to the prior year.
- Capital Expenditures: Confirm the timeline and ROI of the brownfield expansion driving the increase in CapEx to $42.6 million.
- Medical Sector: Assess the sustainability of the 14% decline in Medical sales and the inventory destocking trends in that sector.
- Debt Covenants: Note the strong compliance with credit facility covenants (Interest Coverage: 15.48x; Net Leverage: 0.81x).